Inaqovi

Decitabine, the active ingredient in Inaqovi, is a DNA methyltransferase inhibitor (nucleoside analog) presented as a 35 mg decitabine / 100 mg cedazuridine oral tablet for oral use. It treats myelodysplastic syndromes and chronic myelomonocytic leukemia in adult patients.

GNH USA supplies Inaqovi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Inaqovi is indicated for hematologic disorders that involve abnormal DNA methylation.

Myelodysplastic syndromes (MDS): improves blood cell production and delays progression to acute leukemia. Chronic myelomonocytic leukemia (CMML): reduces disease activity and may extend survival. Myelodysplastic syndrome with 5q deletion: provides disease‑modifying benefit in patients with this cytogenetic abnormality.

Inaqovi may be associated with a range of adverse reactions, which are typically categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: decreased energy levels. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe infection: febrile neutropenia requiring hospitalization. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Before initiating therapy, clinicians should consider several safety measures.

Monitoring blood counts: perform regular CBC to detect myelosuppression. Liver function: assess hepatic enzymes before and during treatment. Renal function: evaluate kidney function as clearance may be affected. Pregnancy: avoid use; teratogenic potential is unknown and contraindicated in pregnancy. Concomitant immunosuppressants: use caution due to heightened infection risk. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Inaqovi can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce cedazuridine exposure. - Anticoagulants (warfarin): increased bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - Other myelosuppressive agents: additive bone‑marrow suppression. - Live vaccines: risk of infection due to immunosuppression. - Proton pump inhibitors: may affect absorption of cedazuridine.